10-Q · May 7, 2026
Bluejay Diagnostics reported comparable net losses of approximately $1.9 million for Q1 2026 and Q1 2025, with no revenue disclosed. Cash and cash equivalents stood at about $3.7 million, and the company continues its…
Earnings analysis · 10-Q
BJDX earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
The filing does not provide revenue, margin, EPS, segment, or cash-flow results in the extracted disclosure, but it highlights a continuing early-stage, loss-making profile and substantial financing dependence. Bluejay…
Read full summary
The filing does not provide revenue, margin, EPS, segment, or cash-flow results in the extracted disclosure, but it highlights a continuing early-stage, loss-making profile and substantial financing dependence. Bluejay held approximately $9.6 million of cash against $2.1 million of current liabilities at June 30, 2026, while reporting a $4.2 million six-month loss and a $45.8 million accumulated deficit. Management expects to raise additional capital to pursue a 510(k) submission in the first half of 2027, but going-concern and Nasdaq delisting risks are material.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
$9.6M cash exceeds current liabilities
Bluejay reported approximately $9.6 million of cash and cash equivalents versus approximately $2.1 million of current liabilities as of June 30, 2026, providing near-term liquidity despite ongoing losses.
-
Targets FDA submission in 1H27
Management’s strategic plan targets submission of a 510(k) regulatory application to the FDA in the first half of 2027, followed by pursuit of FDA approval.
-
Disclosure controls deemed effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no material change in internal control over financial reporting during the quarter.
What to watch
-
Additional financing and going-concern risk
The company incurred a loss of approximately $4.2 million for the six months ended June 30, 2026, had an accumulated deficit of approximately $45.8 million, and does not currently generate operating income. Management expects to need additional capital; failure to obtain financing could lead to liquidation under Chapter 7 bankruptcy laws.
-
Nasdaq bid-price delisting risk
The stock closed at $1.07 per share on August 7, 2026. If it closes below the $1.00 Nasdaq minimum bid price for more than 30 consecutive trading days, the company could face delisting and, because of its January 2026 reverse stock split, would be ineligible for a compliance period before its one-year anniversary.
-
Potential $5M market-value threshold
The company’s market value is near the proposed $5 million Nasdaq minimum value-of-listed-securities threshold. Although the SEC stayed approval on July 29, 2026, the company could face delisting if the rule becomes effective and its market capitalization remains below $5 million for 30 consecutive trading days.
Management's outlook
No numerical revenue or EPS guidance was provided. Management expects to raise additional capital to support its strategic plan, including submitting a 510(k) application to the FDA in the first half of 2027 and seeking FDA approval thereafter.
Earlier filings 4
10-K · March 6, 2026
Bluejay is a pre-revenue diagnostics company developing the Symphony platform and a 20-minute IL-6 sepsis test. The company has enrolled ~583 of a 750-patient target in its SYMON-II pivotal study and transferred…
10-Q · August 7, 2025
Bluejay reported no revenue and a Q2 2025 net loss of $1,956,604 (EPS -$1.41), an improvement versus Q2 2024 net loss of $2,475,380 (EPS -$256.16) primarily driven by lower interest expense and slightly higher operating…
10-Q · May 13, 2025
Bluejay Diagnostics reported a net loss of $1,864,435 for the quarter ended March 31, 2025, an improvement versus a $2,328,465 loss in the prior-year quarter. Cash declined to $3,116,103 from $4,301,945 at December 31,…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.